Aminoguanidine inhibits aortic hydrogen peroxide production, VSMC NOX activity and hypercontractility in diabetic mice

Cardiovascular Diabetology

Volumn 8, Issue , 2009, Pages

  Oak, Jeong Ho ^a   Youn, Ji Youn ^a   Cai, Hua ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGUANIDINE; ANTIDIABETIC AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENZYME INHIBITOR; GUANIDINE DERIVATIVE; HYDROGEN PEROXIDE; NITRIC OXIDE; NOS3 PROTEIN, MOUSE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE;

ANIMAL; AORTA; ARTICLE; C57BL MOUSE; DRUG ANTAGONISM; DRUG EFFECT; ELECTRON SPIN RESONANCE; ENZYMOLOGY; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; MALE; METABOLISM; MOUSE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VASODILATATION;

ANIMALS; AORTA; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; ELECTRON SPIN RESONANCE SPECTROSCOPY; ENZYME INHIBITORS; GUANIDINES; HYDROGEN PEROXIDE; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NADPH OXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; SUPEROXIDES; VASOCONSTRICTION; VASODILATION;

EID: 77449095809     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-8-65     Document Type: Article

References (45)

1. Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, Gatling W, Bingley PJ, Patterson CC. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 2003, 46(6):760-765. 10.1007/s00125-003-1116-6, 12774166.
2. Paterson AD, Rutledge BN, Cleary PA, Lachin JM, Crow RS. The effect of intensive diabetes treatment on resting heart rate in type 1 diabetes: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Diabetes Care 2007, 30(8):2107-2112. 10.2337/dc06-1441, 2654598, 17468351.
3. Goth L, Eaton JW. Hereditary catalase deficiencies and increased risk of diabetes. Lancet 2000, 356(9244):1820-1821. 10.1016/S0140-6736(00)03238-4, 11117918.
4. Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 2001, 17(3):189-212. 10.1002/dmrr.196, 11424232.
5. Sakai K, Matsumoto K, Nishikawa T, Suefuji M, Nakamaru K, Hirashima Y, Kawashima J, Shirotani T, Ichinose K, Brownlee M, et al. Mitochondrial reactive oxygen species reduce insulin secretion by pancreatic beta-cells. Biochem Biophys Res Commun 2003, 300(1):216-222. 10.1016/S0006-291X(02)02832-2, 12480546.
6. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "Causal" antioxidant therapy. Diabetes Care 2003, 26(5):1589-1596. 10.2337/diacare.26.5.1589, 12716823.
7. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999, 84(5):489-497.
8. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000, 87(10):840-844.
9. Feener EP, King GL. Endothelial dysfunction in diabetes mellitus: role in cardiovascular disease. Heart Fail Monit 2001, 1(3):74-82.
10. Natarajan R, Gerrity RG, Gu JL, Lanting L, Thomas L, Nadler JL. Role of 12-lipoxygenase and oxidant stress in hyperglycaemia-induced acceleration of atherosclerosis in a diabetic pig model. Diabetologia 2002, 45(1):125-133. 10.1007/s125-002-8253-x, 11845232.
11. Cai H, Griendling KK, Harrison DG. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 2003, 24(9):471-478. 10.1016/S0165-6147(03)00233-5, 12967772.
12. Aliciguzel Y, Ozen I, Aslan M, Karayalcin U. Activities of xanthine oxidoreductase and antioxidant enzymes in different tissues of diabetic rats. J Lab Clin Med 2003, 142(3):172-177. 10.1016/S0022-2143(03)00110-0, 14532905.
13. Ouslimani N, Mahrouf M, Peynet J, Bonnefont-Rousselot D, Cosson C, Legrand A, Beaudeux JL. Metformin reduces endothelial cell expression of both the receptor for advanced glycation end products and lectin-like oxidized receptor 1. Metabolism 2007, 56(3):308-313. 10.1016/j.metabol.2006.10.010, 17292717.
14. Su J, Lucchesi PA, Gonzalez-Villalobos RA, Palen DI, Rezk BM, Suzuki Y, Boulares HA, Matrougui K. Role of advanced glycation end products with oxidative stress in resistance artery dysfunction in type 2 diabetic mice. Arterioscler Thromb Vasc Biol 2008, 28(8):1432-1438. 10.1161/ATVBAHA.108.167205, 2755261, 18483403.
15. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RA, Warnholtz A, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 2001, 88(2):E14-22.
16. Oak JH, Cai H. Attenuation of angiotensin II signaling recouples eNOS and inhibits nonendothelial NOX activity in diabetic mice. Diabetes 2007, 56(1):118-126. 10.2337/db06-0288, 17192473.
17. Johansen JS, Harris AK, Rychly DJ, Ergul A. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol 2005, 4(1):5. 10.1186/1475-2840-4-5, 1131912, 15862133.
18. Potenza MA, Gagliardi S, Nacci C, Carratu MR, Montagnani M. Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr Med Chem 2009, 16(1):94-112. 10.2174/092986709787002853, 19149564.
19. Stadler K, Jenei V, Somogyi A, Jakus J. Beneficial effects of aminoguanidine on the cardiovascular system of diabetic rats. Diabetes Metab Res Rev 2005, 21(2):189-196. 10.1002/dmrr.501, 15386808.
20. Ara C, Karabulut AB, Kirimlioglu H, Yilmaz M, Kirimliglu V, Yilmaz S. Protective effect of aminoguanidine against oxidative stress in an experimental peritoneal adhesion model in rats. Cell Biochem Funct 2006, 24(5):443-448. 10.1002/cbf.1245, 15991262.
21. Chowdhury P, Soulsby ME, Scott JL. Effects of aminoguanidine on tissue oxidative stress induced by hindlimb unloading in rats. Ann Clin Lab Sci 2009, 39(1):64-70.
22. Szabo C, Ferrer-Sueta G, Zingarelli B, Southan GJ, Salzman AL, Radi R. Mercaptoethylguanidine and guanidine inhibitors of nitric-oxide synthase react with peroxynitrite and protect against peroxynitrite-induced oxidative damage. J Biol Chem 1997, 272(14):9030-9036. 10.1074/jbc.272.14.9030, 9083027.
23. Ihm SH, Yoo HJ, Park SW, Ihm J. Effect of aminoguanidine on lipid peroxidation in streptozotocin-induced diabetic rats. Metabolism 1999, 48(9):1141-1145. 10.1016/S0026-0495(99)90128-2, 10484054.
24. Giardino I, Fard AK, Hatchell DL, Brownlee M. Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis. Diabetes 1998, 47(7):1114-1120. 10.2337/diabetes.47.7.1114, 9648836.
25. Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K, Foiles PG, Freedman BI, Raskin P, Ratner RE, et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004, 24(1):32-40. 10.1159/000075627, 14685005.
26. Thornalley PJ. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 2003, 419(1):31-40. 10.1016/j.abb.2003.08.013, 14568006.
27. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001, 357(Pt 3):593-615. 10.1042/0264-6021:3570593, 1221991, 11463332.
28. Rosca MG, Mustata TG, Kinter MT, Ozdemir AM, Kern TS, Szweda LI, Brownlee M, Monnier VM, Weiss MF. Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am J Physiol Renal Physiol 2005, 289(2):F420-430. 10.1152/ajprenal.00415.2004, 15814529.
29. Kuttler B, Schneider E. Diabetes mellitus in mice induced by multiple subdiabetogenic doses of streptozotocin: age and sex dependence. Acta Biol Med Ger 1982, 41(12):1199-1202.
30. Rees DA, Alcolado JC. Animal models of diabetes mellitus. Diabet Med 2005, 22(4):359-370. 10.1111/j.1464-5491.2005.01499.x, 15787657.
31. Shen KP, Lo YC, Yang RC, Liu HW, Chen IJ, Wu BN. Antioxidant eugenosedin-A protects against lipopolysaccharide-induced hypotension, hyperglycaemia and cytokine immunoreactivity in rats and mice. J Pharm Pharmacol 2005, 57(1):117-125. 10.1211/0022357055137, 15639000.
32. Tay YC, Wang Y, Kairaitis L, Rangan GK, Zhang C, Harris DC. Can murine diabetic nephropathy be separated from superimposed acute renal failure?. Kidney Int 2004, 68(1):391-398.
33. Cai H, McNally JS, Weber M, Harrison DG. Oscillatory shear stress upregulation of endothelial nitric oxide synthase requires intracellular hydrogen peroxide and CaMKII. J Mol Cell Cardiol 2004, 37(1):121-125. 10.1016/j.yjmcc.2004.04.012, 15242742.
34. Chalupsky K, Cai H. Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. Proc Natl Acad Sci USA 2005, 102(25):9056-9061. 10.1073/pnas.0409594102, 1157015, 15941833.
35. Fleischhacker E, Esenabhalu VE, Spitaler M, Holzmann S, Skrabal F, Koidl B, Kostner GM, Graier WF. Human diabetes is associated with hyperreactivity of vascular smooth muscle cells due to altered subcellular Ca2+ distribution. Diabetes 1999, 48(6):1323-1330. 10.2337/diabetes.48.6.1323, 10342823.
36. Chang KC, Chung SY, Chong WS, Suh JS, Kim SH, Noh HK, Seong BW, Ko HJ, Chun KW. Possible superoxide radical-induced alteration of vascular reactivity in aortas from streptozotocin-treated rats. J Pharmacol Exp Ther 1993, 266(2):992-1000.
37. El-Remessy AB, Abou-Mohamed G, Caldwell RW, Caldwell RB. High glucose-induced tyrosine nitration in endothelial cells: role of eNOS uncoupling and aldose reductase activation. Invest Ophthalmol Vis Sci 2003, 44(7):3135-3143. 10.1167/iovs.02-1022, 12824263.
38. Brooks BA, Heffernan S, Thomson S, McLennan SV, Twigg SM, Yue DK. The effects of diabetes and aminoguanidine treatment on endothelial function in a primate model of type 1 diabetes. Am J Primatol 2008, 70(8):796-802. 10.1002/ajp.20550, 18481256.
39. Rodriguez-Manas L, Angulo J, Vallejo S, Peiro C, Sanchez-Ferrer A, Cercas E, Lopez-Doriga P, Sanchez-Ferrer CF. Early and intermediate Amadori glycosylation adducts, oxidative stress, and endothelial dysfunction in the streptozotocin-induced diabetic rats vasculature. Diabetologia 2003, 46(4):556-566.
40. Pieper GM. Enhanced, unaltered and impaired nitric oxide-mediated endothelium-dependent relaxation in experimental diabetes mellitus: importance of disease duration. Diabetologia 1999, 42(2):204-213. 10.1007/s001250051140, 10064101.
41. Hopfner RL, McNeill JR, Gopalakrishnan V. Plasma endothelin levels and vascular responses at different temporal stages of streptozotocin diabetes. Eur J Pharmacol 1999, 374(2):221-227. 10.1016/S0014-2999(99)00316-7, 10422763.
42. Schofield I, Malik R, Izzard A, Austin C, Heagerty A. Vascular structural and functional changes in type 2 diabetes mellitus: evidence for the roles of abnormal myogenic responsiveness and dyslipidemia. Circulation 2002, 106(24):3037-3043. 10.1161/01.CIR.0000041432.80615.A5, 12473548.
43. Bagi Z, Koller A, Kaley G. PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes. Am J Physiol Heart Circ Physiol 2004, 286(2):H742-748. 10.1152/ajpheart.00718.2003, 14551045.
44. El-Khatib AS, Moustafa AM, Abdel-Aziz AA, Al-Shabanah OA, El-Kashef HA. Effects of aminoguanidine and desferrioxamine on some vascular and biochemical changes associated with streptozotocin-induced hyperglycaemia in rats. Pharmacol Res 2001, 43(3):233-240. 10.1006/phrs.2000.0772, 11401414.
45. Dewhurst M, Stevens EJ, Tomlinson DR. Effects of aminoguanidine and N(G)-nitro-L-arginine methyl ester on vascular responses of aortae and lungs from streptozotocin-diabetic rats. Prostaglandins Leukot Essent Fatty Acids 1997, 56(4):317-324. 10.1016/S0952-3278(97)90576-7, 9150378.